The pivotal ANDROMEDA-SHOCK study (2019) demonstrated a decreased mortality rate of eight percentage points among patients with septic shock whose treatment involved a resuscitation strategy targeting capillary refill time (CRT) normalization, compared with a strategy focused on blood lactate levels. Subsequently, the Surviving Sepsis Campaign added CRT monitoring as part of standard practice for treating sepsis.  

This study and the update to clinical guidance directly reinforce the value of the ProMedix PeriFRL CRT monitor that Matthew Hansen MD, MCR and David Sheridan MD, MCR envisioned in 2015. Drs. Hansen and Sheridan’s pursuit of an accurate, digital measure of capillary refill time, designed to assist in the early recognition and treatment of diseases ranging from sepsis to dehydration, and from hemorrhage to cardiogenic shock was developed in concert with Dr. Baker and Welch Allyn. The team filed their first patent in 2016; their first research paper was published the following year. Subsequent development enabled them to refine their discovery, leading to the PeriFRL CRT detector, which currently supports multiple patient studies.  

The problem with CRT monitoring lies in the enormous variability between different provider’s measurements and even between different trials by the same clinician.  

The next evolution: ProMedix PeriFRL Circulatory Dysfunction Monitor

The PeriFRL CRT technology standardizes CRT monitoring and obtains accurate, consistent results. Building on the prior ANDROMEDA-SHOCK study, in 2022 ProMedix launched a prospective, observational study in the ER to determine the ability of PeriFRL to further improve early sepsis detection and increase sepsis survival rates. The results - PeriFRL was as accurate in identifying sepsis as current blood labs. Only, PeriFRL's reading was captured in seconds, rather than the average of over 70 minutes for lab return.